You are here

  • Home
  • Archive
  • Volume 76, Issue Suppl 2
  • THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks

Citation Tools

Article menu

Download PDFPDF

Poster Presentations
Rheumatoid arthritis - non biologic treatment
THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks
Free

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Alten R, Westhovens R, Kavanaugh A, et al
THU0173 Long term safety and efficacy of filgotinib in a phase 2B open label extension study in patients with rheumatoid arthritis: results up to 144 weeks
Annals of the Rheumatic Diseases 2017;76:267.